Journal article icon

Journal article

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

Abstract:
The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed.
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1038/nrneph.2017.94

Authors


More by this author
Department:
Oxford, MSD, Nuffield Dept of Population Health, Clinical Trial Service Unit
Role:
Author
More by this author
Department:
Oxford, MSD, Nuffield Dept of Population Health, Clinical Trial Service Unit
Role:
Author
Publisher:
Nature Publishing Group Publisher's website
Journal:
Nature Reviews Nephrology Journal website
Volume:
13
Issue:
8
Pages:
450-451
Publication date:
2017-07-03
Acceptance date:
2017-06-14
DOI:
EISSN:
1759-507X
ISSN:
1759-5061
Pubs id:
pubs:702717
URN:
uri:442e5b03-97e6-4e31-b993-dec5ab3f0302
UUID:
uuid:442e5b03-97e6-4e31-b993-dec5ab3f0302
Local pid:
pubs:702717
Paper number:
8

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP